Skin healing activity of CS Serum

A Clinical Study to evaluate the Skin healing activity of CS Serum - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/06/111689

Enrollment

Registered

2026-06-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: CS Serum : Test Product: CS Serum Dose: Gently use 2-3 drops for 14 days Route of Administration: Topical Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male or Female with age 18-45. 2) Subjects with normal skin. 3) Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1.Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3. Have open sores or open lesions in the treatment area(s). 4. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 5. Have participated in any interventional clinical trial in the previous 90 days. 6. Have a known sensitivity to any of the constituents of the test product including sensitivities to (mention some of active ingredient s name). 7. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 8. Have not skin related issues.

Design outcomes

Primary

Measure	Time frame
1. change in TEWL 2. change in Erythema Index 3. Change in Skin Texture dermascopy (0-3) Timepoint: At D0, D6 and D20	—

Secondary

Measure	Time frame
1. change in Draize scoreTimepoint: At D6 and D20;1. Subject s Self AssessmentsTimepoint: At D20	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results